Current management options in behçet's disease

Minerva Medica

Volumn 93, Issue 5, 2002, Pages 335-345

  Andrews, J ^a,b   Haskard, D O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Autoimmune diseases; Beh et's syndrome, diagnosis; Beh et's syndrome, epidemiology

Indexed keywords

ALPHA INTERFERON; AMITRIPTYLINE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BECLOMETASONE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; DAPSONE; EYE DROPS; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE ACETONIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; WARFARIN;

ANEURYSM; ANTICOAGULANT THERAPY; ARTHRITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ERYTHEMA NODOSUM; FIBROMYALGIA; GASTROINTESTINAL DISEASE; GENETIC LINKAGE; GENITAL ULCER; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LABORATORY TEST; LOZENGE; MOUTH HYGIENE; MOUTH ULCER; MYALGIA; PANCREATITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; REVIEW; TERATOGENICITY; THROMBOEMBOLISM; UVEITIS; VIRUS INFECTION;

BEHCET SYNDROME; HUMANS; URIC ACID;

EID: 0036818499     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Feigenbaum A. Description of Behçet's syndrome in the Hippocratic third book of endemic diseases. Br J Opthalmol 1956;40:355-7.
2. Behçet H. Uber rezidivierende aphthose, durch ein virus verursachte geschwure am mund, am auge und an den genitalien. Dermatol Wochenschr 1937;105:1152-7.
3. Kaklamani VG, Variopoulos G, Kaklamanis PG. Behçets disease. Semin Arthritis Rheum 1998;27:197-217.
4. International Study Group for Behçet's disease. Criteria for the diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
5. Sakane T. New perspective on Behçet's disease. Int Rev Immunol 1997;14:89-96.
6. Hazleman B. Rheumatic disorders of the eye and the various structures involved. Br J Rheumatol 1996;35:258-68.
7. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S et al. Vascular involvement in Behçet's disease. J Rheumatol 1992;19:402-10.
8. Sagdic K, Ozer ZG, Saba D, Ture M, Cengiz M. Venous lesions in Behçet's disease. Am J Vasc Endovasc Surg 1996;11:437-40.
9. Le Thi Huong D, Wechsler B, Papo T, Piette JC, Bletry O, Vitoux JM et al. Arterial lesions in Behçet's disease. A study of 25 patients. J Rheumatol 1995;22:2103-13.
10. Lie IT. Vascular involvement in Behçet's disease: Arterial and venous and vessels of all sizes J Rheumatol 1992;19:341-3.
11. Marsal S, Falga C, Simeon C, Vilardeu M, Bosch JA. Behçet's disease and pregnancy relationship study. Br J Rheumatol 1997;36:234-8
12. Yazici H, Tuzlaci M, Yurdakul S. A controlled survey of sacroiliitis in Behçet's disease. Ann Rheum Dis 1981;40:558-9.
13. Serdaroglu P. Behçet's disease and the nervous system. J Neurol 1998;245:197-205.
14. Jäger HR, Albrecht T, Curati-Alasonatti WL, Williams EJ, Haskard DO. MRI in neuro-Behçet's syndrome: Comparison of conventional spin-echo and FLAIR pulse sequences. Neuroradiology 1999;41:750-8.
15. Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T. Intestinal involvement in Behçet's disease: Review of 136 surgical cases in the Japanese literature. Dis Colon Rectum 1981;24:103-6.
16. Sakemi T, Yoshiyuki T, Ikeda Y, Suzuki N, Nagasawa K. End-stage renal failure due to crescentic glomemlonephritis in a patient with Behçet's syndrome. Review of the literature. Am J Nephrol 1998;18:321-4.
17. Sitjas D, Puig L, Cuatrecasas M, De Moragas JM. Acute telorile neutrophilic dermatosis (Sweet's syndrome). Int J Dermatol 1993;32:261-8.
18. Budak-Alpdogan T, Demircay Z, Alpdogan O, Direskeneli H, Ergun T, Bayik M et al. Behçet's disease in patients with chronic myelogenous leukemia: Possilole role of interferon-α treatment in the occurrence of Behçet's symptoms. Ann Hematol 1997;74:45-8.
19. Yazici H, Chamberlain MA, Tuzun Y, Yurdakul S, Muftuoglu A. A comparative study of the pathergy reaction among Turkish and British patients with Behçet's disease. Ann Rheum Dis 1984;43:74-5.
20. Hampton KK, Chamberlain MA, Menon DK, Davies JA. Coagulation and fibrinolytic activity in Behçet's disease. Thromb Haemost 1991;66:292-4.
21. Mammo L, Al-Dalaan A, Bahabri SS, Saour JN. Association of factor V Leiden with Behçet's disease. J Rheumatol 1997;24;2196-8.
22. Pickering MC, Haskard DO. Behçet's syndrome. JR Coll Physicians Lond 2000;34:169-77.
23. Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A et al. Vascular involvement in Behçet's disease: Relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002;112:37-43.
24. Cakir N, Yazici H, Chamberlain MA, Barnes CG, Yurdakul S, Atasoy S el al. Response to intradermal injection of monosodium urate crystals in Behçet's syndrome. Ann Rheum Dis 1991;50:634-6.
25. Fresko I, Özsoy Y, Mat C, Melikoglu M, Tunq R, Yazici H. The response to the intradermal injection of monosodium urate in Behçet's syndrome and its comparison to the pathergy test. Yonsei Med J 2001;41(Suppl):L68,25.
26. Direskeneli H. Behçet's disease: Infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001;60:996-1002.
27. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndlrome. J Am Coll Cardiol 2001;37:517-20.
28. Bird Stewart JA. Genetic analysis of families of patients with Behçet syndrome: Data incompatible with autosomal recessive inheritance. Ann Rheum Dis 1986;45:265-8.
29. Mizuki N, Inoko H, Mizuki N, Tanaka H, Kera J, Tsuiji K et al. Human leukocyte antigen serologic and DNA typing of Behçet's disease and its primary association with B51. Invest Opthalmol Vis Sci 1992;33:3332-40.
30. Mizuki N, Ota M, Kimura M, Ohno S, Ando H, Katsuyama Y et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: A strong association of six GCT repetitions with Behçet's disease. Proc Natl Acad Sci USA 1997;94:1298-303.
31. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet's disease. Int Rev Immunol 1997;14:21-32.
32. Mizushima Y, Matsuda T, Hoshi K, Ohno S. Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 1988;15:1029-30.
33. Fresko F, Yazici H, Bayramicli M, Yurdakul S, Mat C. Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet's syndrome. Ann Rheum Dis 1993;52:619-20.
34. Hasan A, Fortune F, Wilson A, Wart K, Shinnick T, Mizushima Y et al. Role of γδ T cells in pathogenesis and diagnosis of Behçet's disease. Lancet 1996;347:78904.
35. Ergun T, Ince U, Eksioglu-Demiralp E, Direskeneli H, Gurbuz O, Gurses L et al. HSP expression in mucocutaneous lesions of Behçet's disease. J Ann Acad Dermatol 2001;45:904-9.
36. Stanford MR, Kasp E, Whiston R, Hasan A, Todryk S, Shinnick T et al. Heat shock protein peptides reactive in patients with Behçet's disease are uveitogenic in Lewis rats. Clin Exp Immunol 1994;97:226-31.
37. Matsui T, Kttrokawa M, Kobata T, Oki S, Azttma M, Tohma S et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999;162:4328-35.
38. Ymamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M. Cellular atttoimmunity to retinal specific antigens in patients with Behçet's disease. Br J Opthalmol 1993;77:584-9.
39. Miyachi Y, Taniguchi S, Ozaki M, Horio T. Colchicine in the treatment of the cutaneous manifestations of Behçet's disease. Br J Dermatol 1981;104:61-9.
40. Sharquie KE. Suppression of Behçet's disease with dapsone. Br J Dermatol 1984;110:493-4.
41. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
42. Ehrlich GE. Behçet disease and the emergence of thalidomide. Ann Intern Med 1998;128:494-5.
43. Powell R, Gardner-Medwin J. Guidelines for the clinical use and dispensing of thalidomide. Postgrad Med J 1994;70:901-4.
44. Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996;192:125-8.
45. Calguneri M, Kiraz S, Ertenli I, Benddi M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's disease. A randomized controlled trial. Arthritis Rheum 1996;39:2062-5.
46. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990;322:281-5.
47. Hamryudan V, Ozyazgan Y, Hizli N, Mat C, Yuldakul S, Tuzun Y et al. Azathioprine in Behçet's syndrome: Effects on long-term prognosis. Arthritis Rheum 1997;40:769-74.
48. Masuda K, Urayama A, Kogure M, Nakajima A, Nakae K, Inaba G. Double-masked trial of cydosporin versus colchicine and long term open study of cyclosporin in Behçet's disease. Lancet 1989;1:1093-6.
49. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999;106:5860.
50. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998;352:35-6.
51. Moehizuki M. Immunotherapy for Behçet's disease. Int Rev Immunol 1997;14:49-66.
52. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease: An update. Semin Arthritis Rheum 2001;30:299-312.
53. Zouboulis CC, Orfanos CE. Treatment of adamantiades-Behget disease with systemic interferon. Arch Dermatol 1998;134:1010-6.
54. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infiiximab. Rheumatology 2001;40:473-4.
55. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6.
56. Radke PW, Schwarz ER, Groesdonk H, Graf J, Janssens U. Thrombosis in Behçet's disease: Report of a case followed by a systematic review using the methodology of evidence based medicine. J Thromb Thrombolysis 2001;11:137-41.